波罗样酶4 (PLK4) 作为乳腺癌治疗点
Armen Parsyan1,2,3,4,5, Harjot Athwal1, Vasudeva Bhat1,2,3
1Department of Anatomy and Cell Biology, Schulich School of Medicine & Dentistry, Western University, London, ON N6A 5C1, Canada.
Carcinogenesis
|October 15, 2025
概括
波罗样酶4 (PLK4) 在癌症发育中至关重要. 抑制PLK4通过减少瘤生长和提高放射疗法的有效性来治疗乳腺癌具有前途.
科学领域:
- 细胞生物学 细胞生物学
- 在瘤学瘤学.
- 分子医学是分子医学.
背景情况:
- 波罗样酶4 (PLK4) 是中心重复和中心成熟的关键调节剂.
- PLK4在包括乳腺癌在内的各种癌症的发展和进展中发挥着重要作用.
- 过度表达PLK4与亲瘤性表型和乳腺癌患者的不良结果有关.
研究的目的:
- 讨论PLK4作为乳腺癌治疗点的作用.
- 突出PLK4与癌症进展和患者结局的关联.
- 审查PLK4抑制剂在癌症治疗中的潜力.
主要方法:
- 对癌症中PLK4的临床前和临床研究的综述.
- 对PLK4对癌细胞增殖,迁移和亡的功能影响的分析.
- 对PLK4抑制剂的研究,如CFI-400945和中心B.
主要成果:
- PLK4上调促进癌细胞的增殖,运动,入侵和对亡的抵抗.
- 乳腺癌中PLK4过度表达与预后不佳和侵袭性亚型相关.
- PLK4抑制剂在减少瘤生长和增强放射治疗方面表现出临床前的有效性.
结论:
- PLK4是乳腺癌治疗的有前途的治疗标.
- 抑制PLK4提供了一种潜在的策略来克服治疗耐药性并改善患者的治疗结果.
- 对PLK4抑制剂进行进一步的临床研究对于乳腺癌治疗是有必要的.
更多相关视频
08:37Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
Published on: November 5, 2014
10.3K
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.6K
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
M-Cdk Drives Transition Into Mitosis
6.2K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K
